top of page
team-of-surgeons-doing-laparoscopic-surgery-looki-2024-10-18-18-03-14-utc-web.jpg

A Defensible, Scalable Asset Poised for Acquisition or Licensing

RightMedLabel™ combines clinical validation, patent protection, and clear market demand – offering acquirers and investors a rare opportunity in the high-value healthcare IP space.

This innovation complements the portfolios of global device, labeling, and operating room supply manufacturers.

Valuation Highlights
Independent Valuation (October 2025)

Period                           Low                         Most Likely                      High
2025 – 2040               $48 M                    $95.9 M                               $143.7 M
2025 – 2028               $9.9 M                    $19.6 M                               $29.3 M

Based on 7.5 % market penetration and 5% royalty rate within a $74 B U.S. market.
Market Growth & Revenue Potential
Expanding Addressable Market Through 2040
•    U.S. Sterile Labeling Market 2025: $3.65 B
•    2040 Forecast: $6.1 B (3.3 % CAGR)
•    15-Year Cumulative Market ≈ $74 B

Even a 1% market share delivers projected royalty income of $38 million. At 7.5%, income rises to $286 million.
Why rightMEDLabel™ Stands Out
  1. Regulatory Alignment
    Built to meet USP, AORN, and Joint Commission standards for sterile labeling compliance.
     
  2. Defensible IP
    U.S. Patent No. 7,815,123 B2, active and enforceable through 2028 with potential extensions.
     
  3. Ready for Licensing or Scale
    Prototype validated in U.S. hospitals; manufacturing and regulatory roadmap established.
     
  4. Broader Applications
    Adaptable for use in lab, pharma, and clean-room environments.
Next Steps: Let’s Discuss Strategic Alignment
RightMedLabel™ is now accepting inquiries from qualified buyers and investment partners. Confidential information available under NDA.

Call Michael McCarthy To Discuss: 610 304 5677
bottom of page